Auriga Reiterates a 'Buy' on Thermo Fisher Scientific (TMO); Year Ends on Strong Note; 2012 Guidance Looks Good

Auriga reiterates a 'Buy' on Thermo Fisher Scientific (NYSE: TMO) price target of $65.00.

Auriga analyst said, "Yesterday, TMO reported 4Q11 sales of $3.13B (+15%; 5% org, 1% acq . and 0 % F/X) and non-GAAP EPS of $1.18 (+23% Y/Y). Revenue and EPS were above consensus and our estimates. Organic revenue growth of 5% was ahead of our expectations (2%) as new product launches, solid demand in emerging markets and a rebound in Academic/Government (~24% of sales) all helped. Global demand remains steady with continued strength in industrial, applied and clinical diagnostic markets, but weakness in Academic and Government will likely continue throughout 2012. Overall, TMO's diverse end markets should help offset the lingering weakness within Academic/Government."

For an analyst ratings summary and ratings history on Thermo Fisher Scientific click here. For more ratings news on Thermo Fisher Scientific click here.

Shares of Thermo Fisher Scientific closed at $54.71 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Thermo Fisher sells microbiology unit to Astorg for $1.075B
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald